Skip to content
Screener

Immix Biopharma, Inc. IMMX Operating Lease Liability - Undiscounted Excess Amount

Operating Lease Liability - Undiscounted Excess Amount at other companies

Artiva Biotherapeutics, Inc. logo
Artiva Biotherapeutics, Inc.ARTV
$1.24M-47.9%
ImmunityBio, Inc. logo
ImmunityBio, Inc.IBRX
$10.5M-13.4%

Other financials

Income statement

See full
Operating income-$10.8M-131%
Net income-$10.1M-122%
EPS (diluted)-$0.18-20.0%

Balance sheet

See full
Cash & equivalents$79.3M+398%
Total debt$1.0M-2.0%
Total equity$84.4M+779%
Total assets$95.8M+382%

Cash flow

See full
Operating cash flow-$9.8M-483%
CapEx$32.5K-52.0%
Free cash flow-$9.9M-462%

Valuation

See full
Market cap$721.15M+982%
Enterprise value$642.94M+1,047%

Returns & leverage

See full
Return on equity-74.4%-18.6pp
Debt / equity-0.1×
Current ratio8.8×+7.0×

Where this comes from

Reported directly by Immix Biopharma, Inc. in its filing.

Tagged under the XBRL concept us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount.

The source filing: Immix Biopharma, Inc.’s 10-Q, filed May 7, 2026.

Filed
May 7, 2026, 5:17 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001493152-26-021764
Line itemOperating / Leases
2027158,325
2028163,866
2029169,602
2030175,538
2031 and thereafter564,344
Total future undiscounted lease payments1,394,403
Less: Interest(356,668)
Present value of lease liabilities$1,037,735

Document

FAQ

What is Immix Biopharma, Inc.'s operating lease liability - undiscounted excess amount?
Immix Biopharma, Inc. (IMMX) reported operating lease liability - undiscounted excess amount of $356.67K in Q1 2026.
How has Immix Biopharma, Inc.'s operating lease liability - undiscounted excess amount changed year-over-year?
Immix Biopharma, Inc.'s operating lease liability - undiscounted excess amount decreased by 18.3% year-over-year, from $436.55K to $356.67K.
What does operating lease liability - undiscounted excess amount mean?
This represents the difference between the total undiscounted future lease payments and the present value of those payments recorded on the balance sheet. It effectively quantifies the interest component embedded within operating lease obligations. It is a measure of the financing cost inherent in the lease portfolio.

Ask your AI about Immix Biopharma, Inc.'s operating lease liability - undiscounted excess amount.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude